Large and Small-Scale Bioprocessing Market Report 2026

The large and small-scale bioprocessing market size has grown rapidly in recent years. It will grow from $67.66 billion in 2025 to $76.73 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to growth of biopharmaceutical manufacturing, increasing investment in biotechnology R&D, expansion of fermentation-based production, rising use of cell culture technologies, development of large-scale stainless steel bioreactors.

The large and small-scale bioprocessing market size is expected to see rapid growth in the next few years. It will grow to $119.99 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for biologics and biosimilars, rising adoption of single-use technologies, growth of personalized and precision medicine, expansion of CDMO services, increasing focus on sustainable bioprocessing methods. Major trends in the forecast period include rising adoption of single-use and modular bioprocessing systems, growing demand for flexible small-scale bioprocessing in R&D, expansion of contract biomanufacturing and outsourcing models, increasing focus on process scalability from lab to commercial scale, rising integration of upstream and downstream bioprocess workflows.

The increasing demand for biologics is expected to drive the growth of the large- and small-scale bioprocessing market in the coming years. Biologics are medicinal products derived from living organisms or their components, including vaccines, blood and blood components, gene therapies, tissues, and recombinant therapeutic proteins. The rising demand for biologics is driven by advancements in biotechnology, a deeper understanding of disease pathways, and the growing need for targeted and personalized treatments. Both large-scale and small-scale bioprocessing play a critical role in the successful development and commercialization of biologics. Small-scale bioprocessing supports early-stage research, process optimization, and feasibility assessments. In contrast, large-scale bioprocessing enables the efficient, consistent, and regulatory-compliant production of biologics for commercial supply. For example, in February 2024, according to the National Library of Medicine, a U.S.-based medical library, the Food and Drug Administration (FDA) approved 55 new drugs in 2023, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), representing a 50% increase compared to the 37 approvals recorded in 2022. Consequently, the rising demand for biologics is fueling the expansion of the large- and small-scale bioprocessing market.

Major companies in the large- and small-scale bioprocessing market are increasingly focusing on innovative solutions such as fixed-bed, low-footprint bioreactor controllers to meet the rising demand for high-productivity, cost-efficient, and scalable viral vector and advanced therapy manufacturing driven by the growth of gene therapies, vaccines, and biologics. A fixed-bed, low-footprint bioreactor controller is a specialized hardware system that manages large-area cell cultures in fixed-bed reactors, offering a compact design, intuitive user interface, and optimized fluid handling compared with traditional large-scale stirred-tank bioreactors that require significant physical space, high capital investment, and complex infrastructure. For instance, in May 2025, Univercells Technologies SA, a Belgium-based bioprocessing company, launched the scale-X Nitro Controller to operate its 200 m² and 600 m² scale-X Nitro fixed-bed bioreactors. The controller is a compact, wheeled unit with a 1.6 m² footprint that fits through standard cleanroom doors, supports both adherent and suspension cultures, and provides highly intuitive control, enabling rapid scale-up from R&D to commercial manufacturing in approximately eight months while reducing cost of goods by 36-82% compared with traditional adherent processes. By combining high productivity with a simplified, space-saving design, the scale-X Nitro Controller helps biomanufacturers, particularly CDMOs and vaccine developers, accelerate development timelines and lower the economic barriers to large-scale viral production.

In February 2025, Thermo Fisher Scientific Inc., a U.S.-based life sciences technology company, acquired the Purification & Filtration business of Solventum Corporation for approximately US$ 4.1 billion. Through this acquisition, Thermo Fisher aims to enhance its bioprocessing portfolio by integrating Solventum’s advanced filtration and membrane technologies, thereby expanding its biologics manufacturing capabilities across both upstream and downstream workflows. Solventum Corporation is a U.S.-based healthcare and materials science company specializing in purification and filtration technologies for biologics, industrial applications, and medical devices.

Major companies operating in the large and small-scale bioprocessing market are F. Hoffmann-La Roche AG, Novartis AG, Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, AbbVie Inc., Amgen Inc., Biogen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Gilead Sciences Inc., Novo Nordisk A/S, CSL Limited, UCB S.A., Samsung Biologics, WuXi Biologics, Boehringer Ingelheim.

North America was the largest region in the large and small-scale bioprocessing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the large and small-scale bioprocessing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the large and small-scale bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the large and small-scale bioprocessing market by increasing costs of imported bioreactors, filtration systems, and specialized bioprocessing consumables. Product segments such as single-use bioreactors, cell culture media, and filtration assemblies are most affected, particularly in North America and Europe due to reliance on global suppliers. Industrial-scale manufacturers face higher capital and operational costs, while small-scale and pilot facilities experience budget constraints. However, tariffs have encouraged regional manufacturing, localized sourcing of consumables, and long-term strengthening of domestic bioprocessing equipment supply chains.

The large and small-scale bioprocessing market research report is one of a series of new reports that provides large and small-scale bioprocessing market statistics, including large and small-scale bioprocessing industry global market size, regional shares, competitors with a large and small-scale bioprocessing market share, detailed large and small-scale bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the large and small-scale bioprocessing industry. This large and small-scale bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Large and small-scale bioprocessing are essential components of the biotechnology and pharmaceutical industries that involve using living cells or their components to obtain desired products, such as pharmaceuticals, chemicals, and biofuels. Large-scale bioprocessing refers to the industrial-level production of biological products involving large bioreactors and extensive infrastructure. In contrast, Small-scale bioprocessing consists of the production of biological products on a smaller scale, often for research, development, pilot studies, or niche markets.

The main products of large and small-scale bioprocessing are bioreactors or fermenters, cell culture products, filtration assemblies, bioreactor accessories, bags and containers, and others. Bioreactors, or fermenters, are vessels designed to support the growth and metabolic activity of microorganisms or cells under controlled conditions to produce desired biological products. The various modes include in-house and outsourced and have several workflows, mainly downstream processing, fermentation, and upstream processing. These are used on a variety of scales, including industrial scale and small scale, and are utilized in biopharmaceuticals, specialty industrial chemicals, and environmental aids applications.

The large and small-scale bioprocessing market consists of revenues earned by entities by providing microbial bioprocessing, plant cell bioprocessing, animal cell bioprocessing, and algal bioprocessing. The market value includes the value of related goods sold by the service provider or included within the service offering. The large and small-scale bioprocessing market also includes sales of incubators, shakers, and cell culture media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.